Clinical Trials

70 enrolled

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2 Recruiting

83 enrolled

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT05564377 2026-04-21

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Stomach Neoplasms

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Phase EARLY_PHASE1 Recruiting

460 enrolled

CNS

Glioblastoma

NCT06008275 2025-11-10

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05274048 2025-10-29

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1 Recruiting

18 enrolled

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05760612 2025-09-25

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Phase 3 Recruiting

300 enrolled

Breast Neoplasms

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

30 enrolled

Carcinoma, Lobular

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Biliary Tract Neoplasms

NCT05388149 2025-01-31

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

15 enrolled